Project Values Rise, but Investors Keep Asking Who Will Pay

Resource stocks produced the week’s biggest moves. Iondrive Limited (ASX:ION) rose 52.94% after an updated study put a US rare earth recovery module at a projected US$243 million after-tax value. Sunrise Energy Metals (ASX:SRL) gained 45.05% after receiving a conditional US$400 million debt commitment for its Syerston scandium project. Recharge Metals (ASX:REC) added 37.50% when new testing found higher tungsten grades at Brandy Hill South.

Big gains came with conditions

Iondrive’s study assumes a high-grade feed supply and recoveries that still need broader process testing. The company has not yet built the plant. That leaves investors waiting for more proof that the projected value can become a working business.

Sunrise now has a possible source of project debt, but the money is conditional. The board still needs to approve construction, sign firm sales agreements and meet the lender’s requirements. Commissioning is planned for the first half of 2028, so the project has several steps ahead.

Recharge’s results improved the case for recovering tungsten alongside copper and other metals. More than 1,000 samples still need testing. Until those results arrive, the size and commercial value of the mineralised area remain uncertain.

Capital decisions split the market

Green & Gold Minerals (ASX:GG1) fell 31.77% after announcing a one-for-two rights issue at 10 cents a share. The offer gives existing holders the right to buy new shares, but the discount and potential increase in the share count worried investors. The money will fund copper, silver, tin and gold drilling at Queensland projects.

Other companies received a better response to funding news. Bannerman Energy (ASX:BMN) completed a A$124 million placement at A$4.00 a share to fund the Etango uranium project through construction and early production. Gateway Mining (ASX:GML), however, fell 7.29% after raising A$45 million at 8 cents a share. The cash supports 120,000 metres of drilling, but the issue will add 562.5 million new shares.

NEXTDC (ASX:NXT) also fell 6.22% after announcing A$1.1 billion of convertible notes. The notes carry a low proposed interest rate, but they can become shares later. That may reduce each existing investor’s ownership. A separate share sale linked to the deal may also put short-term pressure on the price.

Gold and critical minerals remain active

Gold explorers continued to report large drilling results, but prices did not always follow. Brightstar Resources (ASX:BTR) reported 7 metres at 119 grams per tonne gold at Bull Oak, yet its shares fell 9.40%. Forrestania Resources (ASX:FRS) added the Edna May project and lifted its total resource above two million ounces, but fell 14.29%. These moves show that investors also care about funding, mine construction and the time needed to turn a resource into production.

Westgold Resources (ASX:WGX) fell 13.12% despite setting out a plan to produce up to 510,000 ounces of gold by FY29. The plan does not include the Fletcher Zone, which could add about 140,000 ounces a year but still needs more work. A larger production target therefore remains a future possibility, not part of the formal forecast.

In lithium, Core Lithium (ASX:CXO) produced its first spodumene concentrate from the restarted Finniss plant. The company still needs to complete testing before its first new shipment, planned for the December quarter. Elevra Lithium (ASX:ELV) fell 9.38% even after reporting a strong NAL expansion study. Investors may have focused on the large construction programme and the need to deliver each stage on time.

Deals and clinical news add another layer

Corporate activity remained important. St Barbara (ASX:SBM) rose 6.67% after agreeing to sell its remaining Simberi interests for A$453 million while keeping royalties. If the deal completes, cash could approach A$880 million. Regulatory and possible shareholder approvals still stand between the company and completion.

Neurizon (ASX:NUZ) rose 35.71% after a United States government grant opened wider access to its experimental ALS treatment. Up to 200 patients may receive the treatment for as long as 96 weeks. The programme can provide useful safety information, but continued access after the main trial depends on a positive result.

Some stocks showed that an early price jump can fade. Bubs Australia (ASX:BUB) gained 15.00% after receiving permanent US approval for three infant formula products, yet it remained below its reported re-opening price. The approval removes a regulatory barrier, but the company gave no new earnings forecast. Investors still need to see whether sales and profit improve.